INT255001

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.11
First Reported 2008
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 9
Total Number 11
Disease Relevance 12.94
Pain Relevance 3.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
blood 3
RT1-Hb-ps1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
depression 238 99.72 Very High Very High Very High
fluoxetine 5 98.16 Very High Very High Very High
antidepressant 80 95.84 Very High Very High Very High
Bioavailability 3 92.32 High High
sSRI 20 88.76 High High
cva 123 86.16 High High
ischemia 39 80.08 Quite High
tolerance 14 68.28 Quite High
Inflammation 75 55.56 Quite High
Locus ceruleus 5 50.48 Quite High
Disease Link Frequency Relevance Heat
Obesity 96 99.90 Very High Very High Very High
Depression 316 99.72 Very High Very High Very High
Hypoglycemia 9 99.32 Very High Very High Very High
Diabetes Mellitus 577 99.02 Very High Very High Very High
Insulin Resistance 42 96.52 Very High Very High Very High
Acute Coronary Syndrome 12 96.28 Very High Very High Very High
Cv General 3 Under Development 123 86.16 High High
Diabetes Complications 3 85.76 High High
Overweight 10 84.68 Quite High
Body Weight 44 84.16 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In a study with sertraline, glycosylated hemoglobin (HbA1c) levels were reduced during treatment, but did not differ between the sertraline and placebo groups,15,16 whereas no significant reduction in HbA1c levels was observed in patients treated with fluoxetine or paroxetine, although their depressive symptoms were significantly improved.17 Similarly, although escitalopram resulted in a significant reduction of depression score, there was only a small and nonsignificant reduction in fasting blood glucose (FBG) levels and HbA1c levels.18 It would thus appear that selective serotonin reuptake inhibitors (SSRIs) do not have any major effect on metabolic control, even when they produce a significant effect on depressive symptoms.
Negative_regulation (reduced) of HbA1c in blood associated with depression, ssri and fluoxetine
1) Confidence 0.11 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2819761 Disease Relevance 1.90 Pain Relevance 0.72
Indeed, another study of a compound with a marked noradrenergic component, bupropion, found that BMI and HbA1c levels decreased significantly during the acute treatment phase with an association between reduction of depression severity and reduction of HbA1c levels.30 Clearly, further studies are required to investigate the possible importance of the noradrenergic component of antidepressant action on metabolic parameters in diabetes.


Negative_regulation (decreased) of HbA1c associated with antidepressant, depression, diabetes mellitus and obesity
2) Confidence 0.08 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2819761 Disease Relevance 1.43 Pain Relevance 0.27
In a study with sertraline, glycosylated hemoglobin (HbA1c) levels were reduced during treatment, but did not differ between the sertraline and placebo groups,15,16 whereas no significant reduction in HbA1c levels was observed in patients treated with fluoxetine or paroxetine, although their depressive symptoms were significantly improved.17 Similarly, although escitalopram resulted in a significant reduction of depression score, there was only a small and nonsignificant reduction in fasting blood glucose (FBG) levels and HbA1c levels.18 It would thus appear that selective serotonin reuptake inhibitors (SSRIs) do not have any major effect on metabolic control, even when they produce a significant effect on depressive symptoms.
Neg (no) Negative_regulation (reduction) of HbA1c in blood associated with depression, ssri and fluoxetine
3) Confidence 0.08 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2819761 Disease Relevance 1.64 Pain Relevance 0.70
Indeed, another study of a compound with a marked noradrenergic component, bupropion, found that BMI and HbA1c levels decreased significantly during the acute treatment phase with an association between reduction of depression severity and reduction of HbA1c levels.30 Clearly, further studies are required to investigate the possible importance of the noradrenergic component of antidepressant action on metabolic parameters in diabetes.


Negative_regulation (reduction) of HbA1c associated with antidepressant, depression, diabetes mellitus and obesity
4) Confidence 0.08 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2819761 Disease Relevance 1.45 Pain Relevance 0.28
In a study with sertraline, glycosylated hemoglobin (HbA1c) levels were reduced during treatment, but did not differ between the sertraline and placebo groups,15,16 whereas no significant reduction in HbA1c levels was observed in patients treated with fluoxetine or paroxetine, although their depressive symptoms were significantly improved.17 Similarly, although escitalopram resulted in a significant reduction of depression score, there was only a small and nonsignificant reduction in fasting blood glucose (FBG) levels and HbA1c levels.18 It would thus appear that selective serotonin reuptake inhibitors (SSRIs) do not have any major effect on metabolic control, even when they produce a significant effect on depressive symptoms.
Neg (no) Negative_regulation (reduction) of HbA1c in blood associated with depression, ssri and fluoxetine
5) Confidence 0.08 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2819761 Disease Relevance 1.91 Pain Relevance 0.73
Though ranolazine did not appear to significantly lower fasting glucose levels in diabetic patients, there was a statistically significant reduction of HbA1c with ranolazine compared with placebo regardless of concomitant insulin and/or oral hypoglycemic therapy [ranolazine 750 and 1000 mg reduced HbA1c compared with placebo by 0.48 ± 0.18% (p = 0.008) and 0.70 ± 0.18% (p = 0.0002), respectively].
Negative_regulation (reduction) of HbA1c associated with diabetes mellitus
6) Confidence 0.01 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597754 Disease Relevance 0.82 Pain Relevance 0.19
In particular, the decreases in HbA1c seen in insulin-treated patients were greater than those seen in noninsulin-treated patients.
Negative_regulation (decreases) of HbA1c
7) Confidence 0.01 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597754 Disease Relevance 0.67 Pain Relevance 0.09
In the prospective validation of the MERLIN-TIMI 36 trial, ranolazine showed a significant reduction in HbA1c at 4 months compared with placebo (change from baseline –0.30 vs –0.04, p = 0.001).
Negative_regulation (reduction) of HbA1c
8) Confidence 0.01 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597754 Disease Relevance 0.86 Pain Relevance 0.04
Sitagliptin, an orally available DPP-IV inhibitor developed to be used as a once daily treatment for T2DM, has shown beneficial effects on glycaemic control, reducing HbA1c, and preventing hypoglycemia, as well as on islet mass and function, with no relevant adverse effects [16, 17].
Negative_regulation (reducing) of HbA1c associated with hypoglycemia and diabetes mellitus
9) Confidence 0.00 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC2905949 Disease Relevance 0.49 Pain Relevance 0.05
In any case, considering the interesting properties demonstrated by these new class of antidiabetic agents, which make them different from the traditional drugs, and if the clinical studies are able to confirm other influences, apart the already reported glycaemic control and HbA1c reduction, in a near future their place in the treatment algorithm might be reviewed.
Negative_regulation (reduction) of HbA1c
10) Confidence 0.00 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC2905949 Disease Relevance 0.47 Pain Relevance 0
Therefore, chronic sitagliptin treatment has promoted a reduction of glucose and HbA1c levels, together with a partial correction of insulin reduction and an improvement of insulin resistance (HOMA-IR), which is in agreement with other reports [37, 38].
Negative_regulation (reduction) of HbA1c associated with insulin resistance
11) Confidence 0.00 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC2905949 Disease Relevance 1.30 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox